Pharma major Lupin announced that it has received tentative approval for its Apixaban Tablets, 2.5 mg and 5 mg from the United States Food and Drug Administration (FDA) to market a generic version of Bristol-Myers Squibb Company's Eliquis Tablets, 2.5 mg and 5 mg.

Lupin's Apixaban Tablets, 2.5 mg and 5mg is the generic version of Bristol-Myers Squibb Company's Eliquis Tablets, 2.5 mg and 5 mg. It is indicated for:

> reducing the risk of stroke and systemic embolism in nonvalvular atrial fibrillation.

> prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), following hip or knee replacement surgery.

> treatment of DVT and PE and

> reducing the risk of recurrent DVT and PE.

Eliquis Tablets, 2.5 mg and 5 mg had annual sales of approximately USD 6366 million in the US (IQVIA MAT September 2018).

Shares of the company declined Rs 0.05, or 0.01%, to trade at Rs 815.00. The total volume of shares traded was 0 at the BSE (9.01 a.m., Tuesday).